AR103952A1 - Derivados de pirimidina-diona - Google Patents
Derivados de pirimidina-dionaInfo
- Publication number
- AR103952A1 AR103952A1 ARP160100705A ARP160100705A AR103952A1 AR 103952 A1 AR103952 A1 AR 103952A1 AR P160100705 A ARP160100705 A AR P160100705A AR P160100705 A ARP160100705 A AR P160100705A AR 103952 A1 AR103952 A1 AR 103952A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- hydrogen
- group
- compounds
- optionally substituted
- Prior art date
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 206010003805 Autism Diseases 0.000 abstract 1
- 208000020706 Autistic disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000004112 neuroprotection Effects 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente se refiere a compuestos de fórmula (1) en la que: Y es C-R¹; R¹ es hidrógeno, F o Cl; R¹ es F o Cl; R² es hidrógeno o alquilo inferior; R³ es fenilo, piridinilo o isotiazolilo, en el que el átomo de N en el grupo piridinilo puede encontrarse en posiciones diferentes, sustituido opcionalmente con uno o dos átomos de halógeno; R⁴ es hidrógeno o alquilo inferior; Het es un grupo heteroarilo de 5 elementos, que contiene dos o tres heteroátomos, seleccionados de entre N, O ó S, sustituido opcionalmente con alquilo inferior, cicloalquilo, alcoxialquilo inferior, heterocicloalquilo, en el que el heteroátomo es O, o alquilo inferior sustituido con hidroxi, o es un anillo heteroaromático bicíclico, que contiene dos o tres N-heteroátomos seleccionados de entre los restos del grupo de fórmulas (2), o a una sal o sal de adición de ácido farmacéuticamente aceptable, a una mezcla racémica o a su enantiómero y/o isómero óptico y/o estereoisómero correspondiente de los mismos. Los compuestos pueden utilizarse para el tratamiento de la enfermedad de Parkinson, la ansiedad, la emesis, el trastorno obsesivo-compulsivo, el autismo, la neuroprotección, el cáncer, la depresión y la diabetes de tipo 2.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15159868 | 2015-03-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR103952A1 true AR103952A1 (es) | 2017-06-14 |
Family
ID=52684156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160100705A AR103952A1 (es) | 2015-03-19 | 2016-03-17 | Derivados de pirimidina-diona |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10065956B2 (es) |
| EP (1) | EP3271353B1 (es) |
| JP (1) | JP6539749B2 (es) |
| CN (1) | CN107207481B (es) |
| AR (1) | AR103952A1 (es) |
| TW (1) | TWI605042B (es) |
| WO (1) | WO2016146600A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107580598B (zh) | 2015-07-15 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为代谢型谷氨酸受体调节剂的乙炔基衍生物 |
| PE20190382A1 (es) | 2016-07-18 | 2019-03-08 | Hoffmann La Roche | Derivados etinilo |
| BR112021001131A2 (pt) | 2018-07-26 | 2021-04-20 | Domain Therapeutics | derivados de quinazolinona substituídos e seu uso como moduladores alostéricos positivos de mglur4 |
| WO2023048034A1 (ja) * | 2021-09-24 | 2023-03-30 | 東レ・ファインケミカル株式会社 | エチニル基を有する芳香族化合物の製造方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011029104A1 (en) * | 2009-09-04 | 2011-03-10 | Vanderbilt University | Mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8759377B2 (en) * | 2009-11-23 | 2014-06-24 | Vanderbilt University | Substituted dioxopiperidines and dioxopyrrolidines as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| US8420661B2 (en) * | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
| DK3049409T3 (en) * | 2013-09-25 | 2017-07-10 | Hoffmann La Roche | ethynyl derivatives |
| AU2015222303B2 (en) * | 2014-02-25 | 2019-02-28 | F. Hoffmann-La Roche Ag | Ethynyl derivatives |
-
2016
- 2016-03-15 WO PCT/EP2016/055487 patent/WO2016146600A1/en active Application Filing
- 2016-03-15 EP EP16709917.5A patent/EP3271353B1/en active Active
- 2016-03-15 JP JP2017548907A patent/JP6539749B2/ja active Active
- 2016-03-15 CN CN201680007470.8A patent/CN107207481B/zh active Active
- 2016-03-17 AR ARP160100705A patent/AR103952A1/es unknown
- 2016-03-18 TW TW105108581A patent/TWI605042B/zh active
-
2017
- 2017-09-18 US US15/707,848 patent/US10065956B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016146600A1 (en) | 2016-09-22 |
| US10065956B2 (en) | 2018-09-04 |
| TWI605042B (zh) | 2017-11-11 |
| JP6539749B2 (ja) | 2019-07-03 |
| TW201639832A (zh) | 2016-11-16 |
| US20180002333A1 (en) | 2018-01-04 |
| CN107207481A (zh) | 2017-09-26 |
| CN107207481B (zh) | 2020-03-03 |
| JP2018512405A (ja) | 2018-05-17 |
| EP3271353A1 (en) | 2018-01-24 |
| EP3271353B1 (en) | 2019-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018000036A1 (es) | Derivados etinilo | |
| AR121661A2 (es) | Esteroides neuroactivos, composiciones y usos de los mismos | |
| AR099047A1 (es) | Derivados etinilo | |
| AR096640A1 (es) | Derivados de indolin-2-ona o pirrolo-piridin / pirimidin-2-ona | |
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR097721A1 (es) | Derivados de etinilo | |
| EA201592146A1 (ru) | Гетероароматические соединения и их применение в качестве лигандов к дофаминовым d1-рецепторам | |
| AR099640A1 (es) | Derivados de pirrolopiridina o pirazolopiridina | |
| PE20130155A1 (es) | Derivados de ariletinilo | |
| AR103952A1 (es) | Derivados de pirimidina-diona | |
| BR112016026596A2 (pt) | Derivados de indolin-2-ona ou pirrolo-piridin-2-ona, seu uso, composição farmacêutica e combinação | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| PE20151509A1 (es) | Derivado de piridina monociclico | |
| AR092809A1 (es) | 3,5-diaminopirazol como inhibidor de quinasa | |
| PE20181853A1 (es) | 1,5-dihidro-4h-pirazolo[3,4-d]pirimidin-4-onas y 1,5-dihidro-4h-pirazolo[4,3-c]piridin-4-onas como inhibidores de pde1 | |
| AR091781A1 (es) | Antagonistas del receptor de 5-ht3 | |
| MX2016008536A (es) | Derivados de fluoro-naftilo. | |
| EA201590438A1 (ru) | 2-оксо-2,3-дигидроиндолы для лечения расстройств центральной нервной системы | |
| AR085088A1 (es) | Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen | |
| AR110001A1 (es) | Derivados heteroarilo bicíclicos | |
| AR096119A1 (es) | Derivados 2-fenil- o 2- hetaril-imidazol[1,2-a]piridina | |
| AR101359A1 (es) | Derivados de 2-oxa-5-azabiciclo[2.2.1]heptan-3-ilo | |
| AR097739A1 (es) | Imidazo[1,2-a]piridina-7-aminas | |
| EA201692488A1 (ru) | Пептиды, выполняющие роль агонистов окситоцина | |
| AR105662A1 (es) | Derivados de piridina y de pirimidina como inhibidores del eaat3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |